Fulgent Genetics, Inc. (FLGT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$18.66-5.18%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · FLGT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Stated in 3 of 3 supplied quarters. Management reported: “The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.” “Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.”
“The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.”
“The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.”
In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases.
Stated in 2 of 3 supplied quarters. Management reported: “In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases.” “We continue to execute on our strategic initiatives in our laboratory services business as we expand our AI portfolio and integrate digital pathology and are seeing a real impact from our AI tools with improved efficiency and quality.””
“In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases.”
“We continue to execute on our strategic initiatives in our laboratory services business as we expand our AI portfolio and integrate digital pathology and are seeing a real impact from our AI tools wi…”
Paul Kim, Chief Financial Officer, said, “We are pleased with our third quarter results, driven by the improvement in our collection rates.
Stated in 2 of 3 supplied quarters. Management reported: “Paul Kim, Chief Financial Officer, said, “We are pleased with our third quarter results, driven by the improvement in our collection rates.” “We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”” Revenue was $90.412 million in 2026-Q3.
“Paul Kim, Chief Financial Officer, said, “We are pleased with our third quarter results, driven by the improvement in our collection rates.”
“We are maintaining our revenue guidance for the year, and we anticipate gross margins to normalize and further improve in the second half of the year.””
Maintain annual revenue guidance in the range of $330 million to $340 million despite operational challenges.
Progress clinical trials and development of therapeutic candidates FID-007 and FID-022, including presenting Phase 2 data.
Over the trailing year it converted -0.14x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.